PortfoliosLab logoPortfoliosLab logo
IPO Date
Aug 3, 2023

Highlights

EPS (TTM)
-$1.57
EBITDA (TTM)
-$6.93M
Year Range
$0.90 - $2.45
ROA (TTM)
-256.14%
ROE (TTM)
-273.45%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

MIRA Performance Chart

MIRA Pharmaceuticals Inc. Common Stock (MIRA) is down 33.1% since the beginning of the year. At $1 per share, MIRA is trading 58.8% below its 52-week high of $2.


Loading charts...

S&P 500 Index

Returns By Period

MIRA Pharmaceuticals Inc. Common Stock (MIRA) has returned -33.11% so far this year and -26.81% over the past 12 months.


MIRA Pharmaceuticals Inc. Common Stock

1D
-2.88%
1M
-1.94%
YTD
-33.11%
6M
-29.86%
1Y
-26.81%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MIRA Monthly Returns History

Based on dividend-adjusted daily data since Aug 3, 2023, MIRA's average daily return is +0.64%, while the average monthly return is +2.32%. At this rate, an investment would double in approximately 2.5 years.

Historically, 37% of months were positive and 63% were negative. The best month was Jul 2024 with a return of +229.7%, while the worst month was Dec 2023 at -70.4%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.

On a daily basis, MIRA closed higher 40% of trading days. The best single day was Jul 22, 2024 with a return of +627.4%, while the worst single day was Jul 23, 2024 at -48.9%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-17.88%2.42%-15.75%-1.87%0.95%-4.72%-33.11%
20255.26%-16.67%-2.00%18.37%16.38%-10.37%36.36%-16.97%-0.73%22.79%-11.38%2.03%32.46%
2024-10.48%6.91%9.45%-22.74%-3.73%-22.15%229.67%-8.10%-32.64%68.46%-41.10%-11.63%8.57%
2023-15.45%-25.88%-58.28%82.99%-70.42%-85.85%

Benchmark Metrics

MIRA Pharmaceuticals Inc. Common Stock has an annualized alpha of 258.18%, beta of 1.71, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 04, 2023.

  • This stock participated in 277.57% of S&P 500 Index downside but only -61.29% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
258.18%
Beta
1.71
0.00
Upside Capture
-61.29%
Downside Capture
277.57%

Return for Risk

Risk / Return Rank

MIRA ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


MIRA Risk / Return Rank: 2727
Overall Rank
MIRA Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
MIRA Sortino Ratio Rank: 3030
Sortino Ratio Rank
MIRA Omega Ratio Rank: 3030
Omega Ratio Rank
MIRA Calmar Ratio Rank: 2424
Calmar Ratio Rank
MIRA Martin Ratio Rank: 2727
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for MIRA Pharmaceuticals Inc. Common Stock (MIRA) and compare them to S&P 500 Index.


MIRABenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.34

2.24

-2.58

Sortino ratio

Return per unit of downside risk

-0.04

3.07

-3.11

Omega ratio

Gain probability vs. loss probability

1.00

1.41

-0.41

Calmar ratio

Return relative to maximum drawdown

-0.49

2.93

-3.42

Martin ratio

Return relative to average drawdown

-0.79

13.52

-14.31

Dividends

Dividend History


MIRA Pharmaceuticals Inc. Common Stock doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the MIRA Pharmaceuticals Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MIRA Pharmaceuticals Inc. Common Stock was 92.69%, occurring on Jul 9, 2024. The portfolio has not yet recovered.

The current MIRA Pharmaceuticals Inc. Common Stock drawdown is 86.39%.


Related event

Drawdown

Fall

Recovery

Underwater

2024 bear market2024
-92.69%Jul 2024
11mo 10d
2y 10moAug 2023 - now

Drawdown Indicators


MIRABenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-92.69%

-56.78%

-35.91%

Max Drawdown (1Y)

Largest decline over 1 year

-54.46%

-9.10%

-45.36%

Max Drawdown (3Y)

Largest decline over 3 years

-18.90%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-86.39%

-0.74%

-85.65%

Average Drawdown

Average peak-to-trough decline

-78.38%

-10.72%

-67.66%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.04%

1.97%

+32.07%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of MIRA Pharmaceuticals Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how MIRA Pharmaceuticals Inc. Common Stock is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with MIRA

Add MIRA Pharmaceuticals Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with MIRA